Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference ALACHUA, Fla. and TAMPA, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...

Axogen, Inc Reports First Quarter 2024 Financial Results ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024 ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12. Axoguard Nerve...